openPR Logo
Press release

Non-Invasive Prenatal Testing Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes | DelveInsight

05-19-2025 01:35 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Non-Invasive Prenatal Testing Market, DelveInsight

Non-Invasive Prenatal Testing Market, DelveInsight

Global non-invasive prenatal testing (NIPT) market was valued at USD 3,916 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.22%, reaching approximately USD 6,645 million by 2030. This growth is largely driven by an increase in late pregnancies and a higher incidence of chromosomal abnormalities such as Down syndrome, Edwards syndrome, Fragile X syndrome, Klinefelter syndrome, Triple-X syndrome, Turner syndrome, and others.

Additional factors fueling market expansion include enhanced insurance coverage for NIPT, a growing preference among physicians for advanced genetic screening in high-risk pregnancies, a trend toward delayed childbearing, increased pregnancy complications in the second and third trimesters, and ongoing technological advancements in testing equipment. These elements are expected to significantly contribute to the market's development through the forecast period of 2024 to 2030.

DelveInsight's Non-Invasive Prenatal Testing Market Insights report provides the current and forecast market analysis, individual leading Non-Invasive Prenatal Testing companies' market shares, challenges, Non-Invasive Prenatal Testing market drivers, barriers, and trends, and key Non-Invasive Prenatal Testing companies in the market.

Request for a detailed sample report on non-invasive prenatal testing @ https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Non-Invasive Prenatal Testing Market Report

The Non-Invasive Prenatal Testing market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Non-Invasive Prenatal Testing market during the forecast period.
Several prominent companies active in the non-invasive prenatal testing (NIPT) market include PerkinElmer Inc., Natera Inc., Invitae Corporation, CENTOGENE N.V., F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, MedGenome Labs Ltd., Ravgen, Eurofins Scientific, BGI, Illumina Inc., YOURGENE HEALTH, Qiagen, Agilent Technologies Inc., among others.
In August 2022, Natera Inc. submitted a pre-submission to the Food and Drug Administration (FDA) for its Panorama non-invasive prenatal test (NIPT) under the Q-Sub process. The submission, made in June 2022, focused on fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.
In July 2022, Genetic Technologies Limited acquired EasyDNA, expanding its availability of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) on its websites across Europe.
In March 2020, Yourgene Health acquired AGX-DPNI, its distribution partner for the Iona non-invasive prenatal test in France, in a deal worth €2.4 million ($2.7 million) in cash, with potential additional earn-out payments of up to €1.7 million based on sales growth.

In June 2019, Illumina, Inc. launched the VeriSeqTM NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based system for non-invasive prenatal testing. This automated solution enables laboratories to screen for a wider range of chromosomal and sub-chromosomal conditions linked to birth defects and pregnancy complications, beyond the typical NIPT offerings.

To read more about the latest highlights related to the Non-Invasive Prenatal Testing market, get a snapshot of the key highlights entailed in the Global Non-Invasive Prenatal Testing Market Report https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Non-Invasive Prenatal Testing Overview
Non-invasive prenatal testing (NIPT) is a modern genetic screening method used to assess the risk of certain genetic conditions in a fetus, such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). Unlike traditional invasive methods like amniocentesis or chorionic villus sampling (CVS), NIPT is a non-invasive procedure that involves a simple blood test from the pregnant woman, making it safer for both the mother and the baby.

Non-Invasive Prenatal Testing Market Insights

North America is projected to hold the largest share of the non-invasive prenatal testing market in 2023. Factors such as a high preterm birth rate, elevated maternal mortality, and a growing prevalence of chromosomal disorders like Down syndrome are expected to positively influence the market in the region. Additionally, North America's advanced healthcare infrastructure, regulatory approval for new products, high diagnosis rates, widespread adoption and awareness, and the introduction of innovative tests are further contributing to market growth.

Within North America, the United States is the dominant player, both in the region and globally, largely due to the increasing incidence of Down syndrome. According to the Centers for Disease Control and Prevention (CDC) in 2022, around 6,000 babies born annually in the U.S. are diagnosed with Down syndrome, representing approximately 1 in every 700 births.

To know more about why North America is leading the market growth in the Non-Invasive Prenatal Testing market, get a snapshot of the Non-Invasive Prenatal Testing Market Outlook https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Non-Invasive Prenatal Testing Market Dynamics

The non-invasive prenatal testing (NIPT) market is categorized by product type (kits and reagents, instruments), Non-Invasive Prenatal Testing (Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, etc.), end-user (hospitals, diagnostic labs), and geography (North America, Europe, Asia-Pacific, and others).

In 2023, the kits and reagents segment is expected to capture a significant portion of the market share due to the availability of a wide range of NIPT consumables. These innovative kits allow for genetic screening of pregnant women at risk for conditions like Patau, Edwards, and Down syndrome. They are highly reliable, safe, and capable of detecting trisomies 13, 18, and 21 early in pregnancy (as early as 10 weeks). The blood test results are available within about seven days, and the use of these kits can reduce the need for invasive procedures by up to 95%.

For example, the Harmony IVD Kit by Roche, which has been used in over 1.8 million pregnancies, is known for its high accuracy and less than 0.1% false-positive rate for trisomies. Another example is the Vanadis Core T21/T18/T13 Reagent Cartridge by PerkinElmer, which screens for trisomy risks using cell-free DNA from pregnant women.

These factors are expected to significantly drive the growth of the non-invasive prenatal testing market, especially in the kits and reagents segment, throughout the forecast period.

Non-Invasive Prenatal Testing Market Drivers:

Increase in late pregnancies and a higher incidence of chromosomal abnormalities such as Down syndrome, Edwards syndrome, Fragile X syndrome, Klinefelter syndrome, Triple-X syndrome, Turner syndrome, and others


Get a sneak peek at the Non-Invasive Prenatal Testing market dynamics @ https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Coverage: Global
Study Period: 2022 to 2032
Key Non-Invasive Prenatal Testing Companies: PerkinElmer Inc., Natera Inc., Invitae Corporation, CENTOGENE N.V., F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, MedGenome Labs Ltd., Ravgen, Eurofins Scientific, BGI, Illumina Inc., YOURGENE HEALTH, Qiagen, Agilent Technologies Inc., and others.

Which MedTech key players in the Non-Invasive Prenatal Testing market are set to emerge as the trendsetter, explore @ Non-Invasive Prenatal Testing Companies https://www.delveinsight.com/report-store/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents
1. Non-Invasive Prenatal Testing Market Report Introduction
2. Non-Invasive Prenatal Testing Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Non-Invasive Prenatal Testing Market Key Factors Analysis
6. Non-Invasive Prenatal Testing Market Porter's Five Forces Analysis
7. Non-Invasive Prenatal Testing Market Layout
8. Non-Invasive Prenatal Testing Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Invasive Prenatal Testing Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes | DelveInsight here

News-ID: 4023373 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Prenatal

Unlocking the Future of Prenatal Care: Insights into the Australia Non-Invasive …
Australia's NIPT market is growing as more parents choose safe, early screening for chromosomal abnormalities. Driven by rising maternal age, advanced sequencing technology, and increasing awareness, NIPT offers high accuracy without invasive procedures. As labs expand test panels and policymakers consider broader reimbursement, NIPT is reshaping prenatal care, making comprehensive and reliable insights accessible to expecting families across Australia. The Australian non-invasive prenatal testing (NIPT) market is undergoing remarkable growth, transforming
Newborn And Prenatal Genetic Testing Market Size Analysis by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Newborn And Prenatal Genetic Testing market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The market for infant and prenatal genetic testing is anticipated to expand at a compound annual growth rate (CAGR) of 10.5% between
Revolutionizing Prenatal Care: Insights into the Growing Non-Invasive Prenatal T …
Mordor Intelligence has published a new report on the Non-invasive Prenatal Testing Market, offering a comprehensive analysis of trends, growth drivers, and future projections. The global non-invasive prenatal testing (NIPT) market is projected to expand significantly, with expectations to grow from USD 3.90 billion in 2025 to USD 7.35 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13.5%. This growth is primarily attributed to
Prenatal Diagnostics Market Companies Overview 2019 - 2027
Global Prenatal Diagnostics Market: Overview Prenatal diagnostics is a procedure for testing the fetus before birth to determine certain hereditary disorders such as Down's syndrome, genetic diseases, chromosome abnormalities, neural tube defects, and other conditions. In case of high risk related to the birth of a child, it can assist by conducting numerous procedures of genetic testing common testing, and screening. Report Overview @ https://www.transparencymarketresearch.com/prenatal-diagnostics-market.html The global prenatal diagnostics market is segmented on
Non-Invasive Prenatal Testing Market : Lucrative Opportunities
Non-Invasive Prenatal Testing Market: Introduction Transparency Market Research has published a new report titled 'Global Non-Invasive Prenatal Testing Market'. According to the report, the global non-invasive prenatal testing market was valued at approximately US$ 1.3 Bn in 2018. The global non-invasive prenatal testing market is expected to expand at a CAGR of 16.4% during the forecast period from 2019 to 2027. Overview Rise in prevalence of chronic conditions, such as cancer and diabetes,
Prenatal Vitamin Supplements Market: Rising Incidence of Prenatal Defects to Fue …
Global Prenatal Vitamin Supplements Market: Overview Prenatal vitamins are the mineral and vitamin supplements used by during their pregnancy for the healthy development of the fetus. Prenatal vitamins are also recommended by doctors before conception and post conception lactation period. These vitamins are like other common man multivitamins but with different concentration of vitamins and some special vitamins required during pregnancy. Most of these vitamins are prescribed as regulated by U.S.